Key Points Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade. 10 stocks we like better than Kodiak Sciences › Shares of Kodiak Sciences (NASDAQ: KOD) soared 178% on Monday after the eye medicine developer announced positive clinical trial results for two of its leading investigational drug candidates. Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.